You are viewing an expired study

Boston, Massachusetts 02115

  • remitting


The purpose of this study is to determine the safety and tolerability of the drug sirolimus in patients with multiple sclerosis (MS) who have failed other treatments.

Study summary:

MS is a chronic autoimmune disease of the central nervous system in which myelin, the protein sheath that protects nerve cells, is degraded by T cells and macrophages, leading to an eventual loss of neurologic function. MS can be classified as either relapsing-remitting, in which patients experience worsening in symptoms followed by partial or complete recovery of function; or progressive, in which patients have a gradual increase in symptoms, with or without relapses. Standard treatments used to treat relapsing-remitting MS are only modestly effective and may be associated with significant toxicity. There is a need to develop therapies with lower toxicities that can be administered early during the course of disease and have the potential to stop disease progression altogether. Sirolimus has been demonstrated to provide potent immunosuppression in recent clinical trials involving kidney transplantation, and may help people with autoimmune diseases like MS. This study will determine the benefit of sirolimus in MS patients. Blood and urine collection will occur at screening. Participants will take daily doses of sirolimus for 6 months. There will be nine study visits; they will occur at Days 14, 28, 42, 56, 90, 120, 150, 180, and 225. Medication adverse events, concomitant medications, and vital signs will be recorded at Visits 1 through 8. At all visits, patient compliance to the sirolimus regimen will be measured, and blood and urine collection will occur. Physical and neurological exams, magnetic resonance imaging (MRI) brain scans, MS status tests, and a chest x-ray will be conducted at selected times throughout the study.


Inclusion Criteria: - Relapsing-remitting MS - Evidence of demyelination on magnetic resonance imaging (MRI) scan - Expanded Disability Status Scale (EDSS) score between 0 and 6 - Nonresponsive to beta-interferon or Glatiramer acetate therapy - Discontinuation of beta-interferon or Glatiramer acetate therapy within 1 month prior to study entry - Willing to use acceptable methods of contraception Exclusion Criteria: - Primary progressive MS - Prior treatment with immunosuppressants - Steroid therapy within 1 month prior to study entry - Evidence of active infection or cancer - Heart or hematologic dysfunction - High levels of lipids in the blood - Use of lipid-lowering agents - History of cirrhosis or liver disease requiring treatment - History of hepatitis B or C - Active cytomegalovirus infection - Kidney disease requiring treatment - Active lung disease - Diabetes - Hyperthyroidism - HIV infection - Tuberculosis - History of alcohol or drug abuse within 6 months prior to study entry - Claustrophobia or inability to undergo MRI - Pregnancy or breast-feeding



Primary Contact:

Principal Investigator
Samia J. Khoury, MD
Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.